Autoimmune Disorders and Associated Antibodies

Autoimmune disorders occur when the immune system mistakenly attacks healthy cells and tissues in the body. These disorders are often associated with the presence of specific antibodies that can help diagnose and monitor the disease. Here are some examples:

Pernicious Anaemia and Anti-Intrinsic Factor Antibodies
Pernicious anaemia is a type of anaemia caused by a deficiency in vitamin B12. It is associated with the presence of anti-intrinsic factor antibodies, which bind to intrinsic factor and prevent the absorption of vitamin B12 in the gut.

Primary Biliary Cholangitis and Anti-Jo-1 Antibodies
Primary biliary cholangitis is an autoimmune disorder that affects the liver. It is associated with the presence of anti-mitochondrial antibodies, but not anti-Jo-1 antibodies, which are associated with other autoimmune disorders like polymyositis and dermatomyositis.

Myasthenia Gravis and Voltage-Gated Calcium Channel Antibodies
Myasthenia gravis is a neuromuscular disorder that causes muscle weakness and fatigue. It is associated with the presence of anti-acetylcholine receptor antibodies, but not anti-striated muscle antibodies, which are found in other autoimmune disorders.

Granulomatosis with Polyangiitis (GPA) and Anti-Myeloperoxidase (p-ANCA) Antibody
GPA is a type of vasculitis that affects small and medium-sized blood vessels. It is associated with the presence of cytoplasmic antineutrophil cytoplasmic antibodies (c-ANCA), but not p-ANCA, which are found in other types of vasculitis.

Hashimoto’s Thyroiditis and Thyroid-Stimulating Antibodies
Hashimoto’s thyroiditis is an autoimmune disorder that affects the thyroid gland. It is associated with the presence of anti-thyroglobulin and anti-thyroperoxidase antibodies, which attack the thyroid gland and cause inflammation.

Causes and Symptoms of Vitamin B12 Deficiency

Vitamin B12 deficiency can lead to macrocytic anaemia and neurological symptoms. The most common cause of this deficiency is the presence of anti-intrinsic factor antibodies. Intrinsic factor is necessary for the absorption of dietary vitamin B12 in the terminal ileum. Without it, vitamin B12 cannot be absorbed, leading to deficiency and anaemia. Symptoms of vitamin B12 deficiency include fatigue, lethargy, dyspnoea on exertion, and neurological symptoms such as peripheral loss of vibration and proprioception, weakness, and paraesthesiae. If left untreated, it can lead to hepatosplenomegaly, heart failure, and demyelination of the spinal cord, causing ataxia.

Diagnosis can be made with a vitamin B12 level test, which reveals anaemia, often pancytopenia, and a raised MCV. A blood film reveals hypersegmented neutrophils, megaloblasts, and oval macrocytes. Treatment involves replacement of vitamin B12.

Other possible causes of vitamin B12 deficiency include intestinal tapeworm, which is rare, and gastrointestinal malignancy, which causes iron deficiency anaemia with a low MCV. Destruction of the anterior and lateral horns of the spinal cord describes anterolateral sclerosis (ALS), which is characterised by progressive muscle weakness and would not cause anaemia or loss of sensation. Enlargement of the ventricles on head CT indicates hydrocephalus, which could explain the wide-based gait but not the anaemia and other symptoms. A haemoglobin A1c of 12.2% is associated with diabetes, which could explain decreased peripheral sensation to fine touch but would not be associated with megaloblastic anaemia.

Treatment Options for Pernicious Anemia with Hydroxocobalamin

Pernicious anemia is a type of anemia caused by a deficiency in vitamin B12, often due to the presence of anti-intrinsic factor antibodies. Hydroxocobalamin is a form of vitamin B12 that can be used for supplementation in patients with pernicious anemia. Here are some treatment options with hydroxocobalamin:

1. Hydroxocobalamin 1 mg IM three times a week for two weeks, then 1 mg IM every three months: This is the standard dose for patients with pernicious anemia without neurological deficits.

2. Hydroxocobalamin 1 mg IM on alternate days indefinitely: This is used for patients with pernicious anemia and neurological involvement until symptom improvement reaches a plateau, then maintenance involves 1 mg IM every two months.

3. Hydroxocobalamin 1 mg IV three times a week for two weeks, then monthly: This is used for the treatment of cyanide poisoning, not for pernicious anemia.

4. Hydroxocobalamin 1 mg IM three times a week for two weeks, then oral 1 mg hydroxocobalamin: Oral supplementation is not appropriate for patients with pernicious anemia due to absorption issues.

5. Hydroxocobalamin 1 mg subcutaneously three times a week for two weeks, monthly for three months, then 3-monthly: Hydroxocobalamin is administered IM, not subcutaneously.

In conclusion, hydroxocobalamin is an effective treatment option for pernicious anemia, but the dosage and administration route should be carefully considered based on the patient’s individual needs.

Microcytic Anaemia in a 63-Year-Old Female

A Full Blood Count (FBC) analysis has revealed that a 63-year-old female is suffering from microcytic anaemia, which is characterized by low mean corpuscular volume (MCV) and low haemoglobin (Hb) levels. This type of anaemia is typically caused by iron deficiency, which is often the result of blood loss. However, in this case, menorrhagia can be ruled out as the patient is postmenopausal. Therefore, the most likely cause of the microcytic anaemia is peptic ulceration. It is important to note that pernicious anaemia or folate deficiency can cause macrocytosis, which is characterized by elevated MCV levels. Proper diagnosis and treatment are necessary to address the underlying cause of the microcytic anaemia and prevent further complications.

The diagnosis in this scenario is von Willebrand’s disease, which is the most common hereditary bleeding disorder caused by a defective von Willebrand factor. This protein plays a crucial role in haemostasis by assisting in platelet adhesion and stabilising coagulation factor VIII. A deficiency in von Willebrand factor prolongs bleeding time and APTT, but does not affect platelet counts or PT. It is more pronounced in women and may present with menorrhagia. Treatment involves administration of recombinant von Willebrand factor. Haemophilia A, Bernard-Soulier syndrome, Glanzmann’s thrombasthenia, and vitamin K deficiency are other bleeding disorders with different causes and blood test results.

Diagnosis of Multiple Myeloma in a Patient with Pathological Fracture

A man has sustained a pathological fracture after a minor trauma, which is likely due to lytic bone lesions. He also presents with anemia, raised calcium, and ESR, all of which are consistent with a diagnosis of multiple myeloma. This is further supported by his age group for presentation.

Other possible diagnoses, such as osteoporosis, vitamin D deficiency, acute leukemia, and malignancy with metastasis, are less likely based on the absence of specific symptoms and laboratory findings. For example, in osteoporosis, vitamin D and phosphate levels are normal, and ESR and hemoglobin levels are not affected. In vitamin D deficiency, calcium and phosphate levels are usually normal or low-normal, and ESR is not raised. Acute leukemia typically presents with systemic symptoms and normal serum calcium levels. Malignancy with metastasis is possible but less likely without preceding symptoms suggestive of an underlying solid tumor malignancy.

In summary, the patient’s clinical presentation and laboratory findings suggest a diagnosis of multiple myeloma.

Different Types of Blood Cells and their Progenitor Cells

Blood cells are formed from different types of progenitor cells. The common myeloid progenitor cell gives rise to myeloblasts, pro-erythroblasts, megakaryoblasts, and monoblasts. Myeloblasts produce granulocytes, while pro-erythroblasts produce red blood cells. Megakaryoblasts give rise to megakaryocytes and platelets, and monoblasts produce monocytes that can become tissue-specific macrophages. B cells, NK cells, and T cells are derivatives of the common lymphoid progenitor cell. Plasma cells, which are antibody-secreting cells, are derived from B cells. Understanding the different types of blood cells and their progenitor cells is important for studying blood disorders and developing treatments.

Management of Acute Haemolytic Transfusion Reaction

When a patient experiences a temperature rise of more than 2°C, abdominal pain, and hypotension after a blood transfusion, an acute haemolytic transfusion reaction should be suspected. In such cases, the transfusion must be stopped immediately, and the set should be taken down. Saline infusion should be initiated to maintain the patient’s blood pressure.

The blood bank should be notified of the suspected reaction, and a sample may need to be collected for further investigation. However, the priority is to manage the patient’s symptoms and prevent further complications. If the reaction is severe, the transfusion should not be continued.

In summary, prompt recognition and management of acute haemolytic transfusion reactions are crucial to prevent serious complications. Healthcare providers should be vigilant in monitoring patients who receive blood transfusions and act quickly if any adverse reactions occur.

Delayed Transfusion Haemolysis: A Possible Cause for Minimal Increase in Haemoglobin

A patient who has received a 3-unit transfusion has only shown a minimal increase in haemoglobin levels, which is a cause for concern. The rise in bilirubin without a corresponding increase in liver enzymes suggests haemolysis from a delayed transfusion haemolysis reaction. This type of reaction occurs when a patient without certain red cell antigens is exposed to these antigens through blood transfusion, resulting in the development of new antibodies and haemolysis after 3-14 days. Symptoms include fevers, rigors, rash, and jaundice, which are less severe and more gradual in onset than acute haemolytic reactions.

Medical management of this patient will involve screening for a wider range of possible antigens and access to a blood bank with a sufficient number of available units for a clean transfusion. Serious complications of blood transfusion are rare due to screening techniques, leukocyte depletion, and improved collection and storage.

Other potential transfusion-related reactions and their approximate time-course include hyperacute (minutes to hours), acute (hours to days), and late (days or longer). Bacterial sepsis is a possible reaction that would occur most likely in the acute time course, but it does not explain the minimal increase in haemoglobin following a 3-unit transfusion. Further haemorrhage, cholestasis of pregnancy, and disseminated intravascular coagulation (DIC) are also unlikely causes.

In conclusion, delayed transfusion haemolysis is a possible cause for the minimal increase in haemoglobin levels in this patient. It is important to consider this reaction and manage it appropriately to prevent further complications.

Factor V Leiden: A Genetic Condition Affecting Blood Clotting

Factor V is a protein that acts as a cofactor to allow the generation of an enzyme called thrombin, which is responsible for cleaving fibrinogen to fibrin. This process leads to the formation of a dense meshwork that makes up the majority of a clot. Activated protein C (aPC) is a natural anticoagulant that limits clotting by degrading factor V. However, in individuals with Factor V Leiden, a genetic condition that is inherited in an autosomal dominant manner, the coagulation factor cannot be destroyed by aPC.

Factor V Leiden is caused by a single nucleotide substitution of adenine for guanine in the gene encoding factor V. This mutation changes the protein’s 506th amino acid from arginine to glutamine, which prevents efficient inactivation of factor V. As a result, factor V remains active, leading to overproduction of thrombin and excess fibrin generation, which in turn causes excess clotting.

In summary, Factor V Leiden is a genetic condition that affects blood clotting by preventing the efficient inactivation of factor V. This leads to excess clotting, which can increase the risk of developing blood clots and related complications.